{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T02:48:38Z","timestamp":1740106118191,"version":"3.37.3"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":338,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Parasitology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.exppara.2023.108490","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T01:26:02Z","timestamp":1676856362000},"page":"108490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A functional assay using human whole blood and flow cytometry analysis to evaluate cytotoxicity and immunomodulatory effect of anti-Trypanosoma cruzi drugs"],"prefix":"10.1016","volume":"247","author":[{"given":"Mariana Eduarda A.S. A.","family":"Lopes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana M.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9a","family":"Teixeira-Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvane M.F.","family":"Murta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine M.","family":"Souza-Fagundes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.exppara.2023.108490_bib1","article-title":"Distinct treatment outcomes of antiparasitic therapy in Trypanosoma cruzi-infected children is associated with early changes in cytokines, chemokines, and T-Cell phenotypes","volume":"13","author":"Albareda","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.exppara.2023.108490_bib2","article-title":"In vitro drug screening against all life cycle stages of Trypanosoma cruzi using parasites expressing \u03b2-galactosidase","volume":"177","author":"Alonso","year":"2021","journal-title":"JoVE"},{"issue":"20","key":"10.1016\/j.exppara.2023.108490_bib3","article-title":"Mecanismos espec\u00edficos de patogenicidade de protozo\u00e1rios intracelulares: Trypanosoma cruzi, Leishmania spp, Toxoplasma gondii e Plasmodium spp","volume":"13","author":"Barros","year":"2012","journal-title":"Revista Liberato"},{"issue":"567","key":"10.1016\/j.exppara.2023.108490_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb7656","article-title":"A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease","volume":"12","author":"Bustamante","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.exppara.2023.108490_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijid.2018.11.369","article-title":"Elevated IL-17 levels and echocardiographic signs of preserved myocardial function in benznidazole-treated individuals with chronic Chagas' disease","volume":"79","author":"Camara","year":"2019","journal-title":"Int. J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.exppara.2023.108490_bib6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.imbio.2014.12.006","article-title":"Etiological treatment of Chagas disease patients with benznidazole lead to a sustained pro-inflammatory profile counterbalanced by modulatory events","volume":"220","author":"Campi-Azevedo","year":"2015","journal-title":"Immunobiology"},{"issue":"1","key":"10.1016\/j.exppara.2023.108490_bib7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1590\/S0074-02762009000900032","article-title":"Immunological and non-immunological effects of cytokines and chemokines in the pathogenesis of chronic Chagas disease cardiomyopathy","volume":"104","author":"Cunha-Neto","year":"2009","journal-title":"Mem. Inst. Oswaldo Cruz"},{"issue":"1","key":"10.1016\/j.exppara.2023.108490_bib8","doi-asserted-by":"crossref","DOI":"10.1590\/S1516-84842010005000011","article-title":"Efeitos quantitativos da estocagem de sangue perif\u00e9rico nas determina\u00e7\u00f5es do hemograma automatizado","volume":"32","author":"Dalanhol","year":"2010","journal-title":"Rev. Bras. Hematol. Hemoter."},{"issue":"4","key":"10.1016\/j.exppara.2023.108490_bib9","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0008-6363(00)00142-5","article-title":"Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure","volume":"47","author":"Damas","year":"2000","journal-title":"Cardiovasc. Res."},{"issue":"5","key":"10.1016\/j.exppara.2023.108490_bib10","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1590\/0037-8682-0025-2017","article-title":"Ex vivo T-lymphocyte chemokine receptor phenotypes in patients with chronic Chagas disease","volume":"50","author":"De Miranda","year":"2017","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"10.1016\/j.exppara.2023.108490_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41579-022-00777-y","article-title":"Anti-trypanosomatid drug discovery: progress and challenges","author":"De Rycker","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"issue":"10","key":"10.1016\/j.exppara.2023.108490_bib12","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.imbio.2012.01.014","article-title":"Impaired phagocytic capacity driven by downregulation of major phagocytosis-related cell surface molecules elicits an overall modulatory cytokine profile in neutrophils and monocytes from the indeterminate clinical form of Chagas disease","volume":"217","author":"Gomes","year":"2012","journal-title":"Immunobiology"},{"issue":"11","key":"10.1016\/j.exppara.2023.108490_bib13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-3024.2009.01108.x","article-title":"The role of parasite persistence in pathogenesis of Chagas heart disease","volume":"31","author":"Gutierrez","year":"2009","journal-title":"Parasite Immunol."},{"issue":"15","key":"10.1016\/j.exppara.2023.108490_bib14","doi-asserted-by":"crossref","first-page":"130088","DOI":"10.1074\/jbc.M111.230847","article-title":"Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites","volume":"286","author":"Hall","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.exppara.2023.108490_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1128\/AAC.05135-11","article-title":"Activation of benznidazole by trypanosomal type I nitrorecdutases results in glyoxal formation","volume":"56","author":"Hall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2023.108490_bib16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ijcard.2015.07.040","article-title":"Inflammatory and cardiac biomarkers are differentially expressed in clinical stages of Chagas disease","volume":"199","author":"Keating","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.exppara.2023.108490_bib17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1590\/S0074-02761990000400003","article-title":"Effect of the host specific treatment in the phagocytosis of Trypanosoma cruzi forms by mouse peritoneal macrophages","volume":"85","author":"Lages-Silva","year":"1990","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.exppara.2023.108490_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0022-1759(97)00138-5","article-title":"Strategies for phenotyping apoptotic peripheral human lymphocytes comparing ISNT, annexin-V and 7-AAD cytofluorometric staining methods","volume":"209","author":"Lecoeur","year":"1997","journal-title":"J. Immunol. Methods"},{"issue":"7","key":"10.1016\/j.exppara.2023.108490_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006612","article-title":"Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discovery","volume":"12","author":"MacLean","year":"2018","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"8","key":"10.1016\/j.exppara.2023.108490_bib20","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1590\/S0100-879X2003000800020","article-title":"Trypanosoma cruzi infection: a continuous invader-host cell cross talk with participation of extracellular matrix and adhesion and chemoattractant molecules","volume":"36","author":"Marino","year":"2003","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.exppara.2023.108490_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/jac\/46.1.137","article-title":"In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi","volume":"46","author":"Molina","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.exppara.2023.108490_bib22","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","article-title":"Randomized trial of posaconazole and benznidazole for chronic Chagas\u2019disease","volume":"370","author":"Molina","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exppara.2023.108490_bib23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/QCO.0000000000000192","article-title":"The use of posaconazole against Chagas disease","volume":"28","author":"Molina","year":"2015","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.exppara.2023.108490_bib24","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1038\/srep04703","article-title":"Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development","volume":"4","author":"Moraes","year":"2014","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.exppara.2023.108490_bib25","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jacc.2016.12.023","article-title":"Benznidazole and posaconazole eliminating parasites in asymptomatic T. cruzi carries: the STOP-CHAGAS trial","volume":"69","author":"Morillo","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.exppara.2023.108490_bib26","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/PL00008532","article-title":"Setting of a colorimetric method to determine the viability of Trypanosoma cruzi epimastigotes","volume":"86","author":"Muelas-Serrano","year":"2000","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.exppara.2023.108490_bib27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1365-3024.1999.00251.x","article-title":"In-vivo treatment with benznidazole enhances phagocytosis, parasite destruction and cytokine release by macrophages during infection with a drug-susceptible but not with a drug-resistant Trypanosoma cruzi population","volume":"21","author":"Murta","year":"1999","journal-title":"Parasite Immunol."},{"issue":"5","key":"10.1016\/j.exppara.2023.108490_bib28","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1189\/jlb.0309187","article-title":"CCL2\/MCP-1 controls parasite burden, cell infiltration, and mononuclear activation during acute Trypanosoma cruzi infection","volume":"86","author":"Paiva","year":"2009","journal-title":"J. Leukoc. Biol."},{"issue":"3","key":"10.1016\/j.exppara.2023.108490_bib29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1590\/S1679-45082015RB3438","article-title":"Chemokines and immunity","volume":"13","author":"Palomino","year":"2015","journal-title":"Einstein"},{"issue":"1","key":"10.1016\/j.exppara.2023.108490_bib30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.intimp.2013.11.003","article-title":"Serum levels of cytokines and chemokines associated with cardiovascular disease in Brazilian patients treated with statins for dyslipidemia","volume":"18","author":"Pereira","year":"2014","journal-title":"Int.Immunopharmacol."},{"key":"10.1016\/j.exppara.2023.108490_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.exppara.2020.107940","article-title":"An ex vivo multiparametric flow cytometry assay using human whole blood to simultaneously measure cytotoxicity and leishmanicidal activities","volume":"216","author":"Ribeiro","year":"2020","journal-title":"Exp. Parasitol."},{"issue":"2","key":"10.1016\/j.exppara.2023.108490_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00436-006-0126-y","article-title":"Development of resazurin microtiter assay for drug sensibility testing of Trypanosoma cruzi epimastigotes","volume":"99","author":"Rol\u00f3n","year":"2006","journal-title":"Parasitol. Res."},{"issue":"5","key":"10.1016\/j.exppara.2023.108490_bib33","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.4269\/ajtmh.16-0761","article-title":"Experimental and clinical treatment of chagas disease: a review","volume":"97","author":"Sales-Junior","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.exppara.2023.108490_bib34","article-title":"Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure","author":"S\u00e1nchez-Vald\u00e9z","year":"2018","journal-title":"Elife"},{"issue":"5","key":"10.1016\/j.exppara.2023.108490_bib35","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1365-3083.2006.01843.x","article-title":"Benznidazole treatment during early-indeterminate Chagas' disease shifted the cytokine expression by innate and adaptive immunity cells toward a type 1-modulated immune profile","volume":"64","author":"Sathler-Avelar","year":"2006","journal-title":"Scand. J. Immunol."},{"issue":"2","key":"10.1016\/j.exppara.2023.108490_bib36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.micinf.2007.10.009","article-title":"Etiological treatment during early chronic indeterminate Chagas disease incites an activated status on innate and adaptive immunity associated with a type 1-modulated cytokine pattern","volume":"10","author":"Sathler-Avelar","year":"2008","journal-title":"Microb. Infect."},{"issue":"12","key":"10.1016\/j.exppara.2023.108490_bib37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/1471-2334-12-123","article-title":"Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with Trypanosoma cruzi antigens","volume":"24","author":"Sathler-Avelar","year":"2012","journal-title":"BMC Infect. Dis."},{"issue":"5","key":"10.1016\/j.exppara.2023.108490_bib38","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1006\/bcmd.1999.0254","article-title":"Measurement of phosphatidylserine exposure in leukocytes and platelets by whole-blood flow cytometry with annexin V","volume":"25","author":"Tait","year":"1999","journal-title":"Blood Cells Mol. Dis."},{"issue":"7","key":"10.1016\/j.exppara.2023.108490_bib39","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1086\/381892","article-title":"Elevated concentrations of CCL2 and tumor necrosis factor\u2013a in chagasic cardiomyopathy","volume":"38","author":"Talvani","year":"2004","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.exppara.2023.108490_bib40","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1128\/AAC.42.7.1771","article-title":"Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies","volume":"42","author":"Urbina","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2023.108490_bib41","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1128\/AAC.44.9.2498-2502.2000","article-title":"In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi","volume":"44","author":"Urbina","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2023.108490_bib42","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.pt.2003.09.001","article-title":"Specific chemotherapy of Chagas disease: controversies and advances","volume":"19","author":"Urbina","year":"2003","journal-title":"Trends Parasitol."},{"issue":"1","key":"10.1016\/j.exppara.2023.108490_bib43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0924-8579(02)00273-X","article-title":"In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease","volume":"21","author":"Urbina","year":"2003","journal-title":"Int. J. Antimicob. Agents"},{"issue":"1\u20132","key":"10.1016\/j.exppara.2023.108490_bib44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.actatropica.2009.10.023","article-title":"Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches","volume":"115","author":"Urbina","year":"2010","journal-title":"Acta Trop."},{"issue":"4","key":"10.1016\/j.exppara.2023.108490_bib45","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s00436-005-1300-3","article-title":"A new pharmacological screening assay with Trypanosoma cruzi epimastigotes expressing beta-galactosidase","volume":"95","author":"Vega","year":"2005","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.exppara.2023.108490_bib46","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.actatropica.2016.09.010","article-title":"Changes in the imune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease","volume":"164","author":"Vallejo","year":"2016","journal-title":"Acta Trop."},{"year":"2020","series-title":"Chagas disease (American trypanosomiasis)","key":"10.1016\/j.exppara.2023.108490_bib47"},{"key":"10.1016\/j.exppara.2023.108490_bib48","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399409001252","article-title":"Trypanocidal drugs: mechanisms, resistance and new targets","author":"Wilkinson","year":"2009","journal-title":"Expet Rev. Mol. Med."},{"issue":"7","key":"10.1016\/j.exppara.2023.108490_bib49","doi-asserted-by":"crossref","DOI":"10.1590\/S0074-02762009000700021","article-title":"A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI","volume":"104","author":"Zingales","year":"2009","journal-title":"Mem. Inst. Oswaldo Cruz"}],"container-title":["Experimental Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014489423000310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014489423000310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T20:45:16Z","timestamp":1736369116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014489423000310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":49,"alternative-id":["S0014489423000310"],"URL":"https:\/\/doi.org\/10.1016\/j.exppara.2023.108490","relation":{},"ISSN":["0014-4894"],"issn-type":[{"type":"print","value":"0014-4894"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A functional assay using human whole blood and flow cytometry analysis to evaluate cytotoxicity and immunomodulatory effect of anti-Trypanosoma cruzi drugs","name":"articletitle","label":"Article Title"},{"value":"Experimental Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exppara.2023.108490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108490"}}